Top Markets
#1 Cortex Cortex +32.82%
#2 龙虾 (Lobster) 龙虾 (Lobster) +32.56%
#3 Akedo Akedo +23.89%
#4 DexNet DexNet +23.19%
#5 Pons Pons +16.16%
#6 wojak wojak +15.73%
#7 OpenEden OpenEden +15.27%
#8 APEX APEX +13.92%
#9 The Black Bull The Black Bull +10.83%
#10 Official Trump Official Trump +9.80%
Coin of the day
Cortex Cortex
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
HBM Holdings Limited HBM Holdings Limited

HBM Holdings Limited

2142
Classement en actions #7297
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused... HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Prix de l'action
$1.95
Capitalisation boursière
$1.64B
Changement (1 jour)
-6.69%
Changement (1 an)
19.42%
Pays
CN
Échange HBM Holdings Limited (2142)

Catégorie

Healthcare
Bénéfices pour HBM Holdings Limited (2142)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de HBM Holdings Limited, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour HBM Holdings Limited de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH